Crossmark

444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.444

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Felices, Martin

Warlick, Erica

Juckett, Mark

Weisdorf, Daniel

Vallera, Daniel

Miller, Sarah

Wangen, Rose

Lewis, Dixie

Knox, JoAnne

Schroeder, Martin

Miller, Jeffrey
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03214666 at ClinicalTrials.gov

Documents that mention this clinical trial

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
https://doi.org/10.1136/jitc-2020-000810

444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients
https://doi.org/10.1136/jitc-2021-sitc2021.444

Document is current

Any future updates will be listed below